Tempora - A New Chewable Spironolactone Tablet For Dogs From Alstoe

Alstoe Ltd has introduced a chewable, flavoured, spironolactone tablet for dogs called Tempora. This is indicated in the treatment of congestive heart failure (CHF) arising from mitral valve disease and can be used alone or in conjunction with standard therapies. Compliance can be an issue with any prescribed medication and may result in sub-optimal treatment regimes. Tempora’s effective flavouring technology, tablet shape with accurate two and four way break tablets not only facilitates ease of use but provides confidence in enhanced compliance. These benefits when combined with excellent affordability provide optimal value to clients. It is estimated that in 75% of dogs with CHF, degenerative mitral valve disease is the underlying cause. Alstoe’s addition of a new tailor made spironolactone tablet offers an expansion to its cardiology sector which includes Nelio an ACE inhibitor. Spironolactone shows clear benefits in treating mxyomatous mitral valve disease (MMVD) in dogs. Acting as an aldosterone receptor antagonist it counteracts the negative consequences of aldosterone production such as myocardial fibrosis and myocardial and vascular remodelling. In addition to offering lunchtime practise seminars Alstoe has designed a Sleep Respiratory Rate (SRR) chart to assist veterinary professionals with ongoing monitoring of their canine patients condition and response to treatment. The use of this can enhance owner compliance and participation in the therapeutic plan. They are available in pads from the company or as a printable download from the website.

More from

• IVC Evidensia assembles expert team to run new £10m referral hospital
• Home delivery service can increase pet health plan sign-ups by 25%
• Research reveals vital clues to help fight anthelmintic resistance
• Lifetime Achievement Award recognises Harrogate vet’s dedication to improving the health and welfare of rabbits
• Bake sale at Leicestershire vet practice for good cause